Category lists following implementation of the Windsor Framework

AI Summary

This guidance document clarifies significant changes to the regulatory landscape for medicinal products in the United Kingdom following the implementation of the Windsor Framework. The primary shift involves products that were historically governed by the European Union’s centralized procedure. Under the new framework, these medicines are now licensed across all of the UK exclusively under national UK law. Conversely, medicinal products falling outside this specific scope continue to be authorized UK-wide under a blend of UK law and relevant EU regulations, including Regulation (EU) 2023/1182 and Directive (EU) 2022/642, a practice consistent with the protocols established on January 1, 2021. While this text represents a general regulatory update rather than an enforcement action against a specific company, it applies to all pharmaceutical manufacturers operating within the UK market. There are no violations or inspection dates cited; instead, the document focuses on compliance with the updated legal framework. To ensure administrative transparency and regulatory certainty, the MHRA mandates that all holders of marketing authorizations—and those submitting new applications—must clearly indicate the specific category of their products. This categorization is essential for identifying which legal standards apply to each authorization, ensuring that both new and existing medicinal products remain compliant with the evolving jurisdictional requirements of the Windsor Framework.